Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-acting cabotegravir + rilpivirine in people living with HIV-1 aged 60 years or older
2022-502882-53-00Phase 4Authorised
- Sponsor
- Fundación para la Formación e Investigación Sanitaria
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cabotegravir and rilpivirine long-acting in Human immunodeficiency virus infection type 1, sponsored by Fundación para la Formación e Investigación Sanitaria. Primary endpoint: Proportion with HIV-1 RNA at least 50 copies/mL at month 12. Planned start Jan 2025; status: authorised.
02
Drugs
cabotegravirrilpivirine long-acting
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2022-502882-53-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502882-53-00.